Related Experiment Video
Updated: Mar 3, 2026
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Emerging Therapies for Childhood Polycystic Kidney Disease
William E Sweeney1, Ellis D Avner1
1Department of Pediatrics, Medical College of Wisconsin, Children's Research Institute, Children's Hospital Health System of Wisconsin, Milwaukee, WI, USA.
Insights
Understanding the genetic and functional interactions between autosomal recessive polycystic kidney disease (ARPKD) and autosomal dominant polycystic kidney disease (ADPKD) may lead to shared therapeutic strategies for childhood cystic kidney diseases.
Area of Science:
- Nephrology
- Genetics
- Molecular Biology
Background:
- Cystic kidney diseases are hereditary disorders characterized by renal cysts.
- Pediatric polycystic kidney disease (PKD) primarily involves autosomal recessive (ARPKD) and autosomal dominant (ADPKD) forms.
- Significant advancements have been made in understanding the molecular and cellular basis of renal cystogenesis in ARPKD and ADPKD.
Purpose of the Study:
- To explore the complex molecular and cellular mechanisms underlying renal cyst formation in ARPKD and ADPKD.
- To investigate the genetic and functional interactions between ARPKD and ADPKD.
- To determine the potential for shared therapeutic approaches for both forms of childhood PKD.
Main Methods:
- Review of current research on the molecular genetics of ARPKD and ADPKD.
- Analysis of gene and protein interactions within the context of cystic phenotypes.
- Evaluation of shared phenotypic abnormalities to identify therapeutic overlaps.
Main Results:
- ARPKD and ADPKD genes and protein products exhibit complex genetic and functional interactions.
- Shared "cystic phenotypes" are observed in both ARPKD and ADPKD.
- These interactions suggest potential efficacy of ADPKD therapies for ARPKD.
Conclusions:
- Knowledge of molecular interactions is crucial for developing effective therapies for childhood PKD.
- Therapeutic strategies for ADPKD may be applicable to ARPKD.
- Treatment decisions should consider disease stage and progression rate alongside molecular insights.
Abstract:
Cystic kidney diseases comprise a varied collection of hereditary disorders, where renal cysts comprise a major element of their pleiotropic phenotype. In pediatric patients, the term polycystic kidney disease (PKD) commonly refers to two specific hereditary diseases, autosomal recessive polycystic kidney disease (ARPKD) and autosomal dominant polycystic kidney disease (ADPKD). Remarkable progress has been made in understanding the complex molecular and cellular mechanisms of renal cyst formation in ARPKD and ADPKD. One of the most important discoveries is that both the genes and proteins products of ARPKD and ADPKD interact in a complex network of genetic and functional interactions. These interactions and the shared phenotypic abnormalities of ARPKD and ADPKD, the "cystic phenotypes" suggest that many of the therapies developed and tested for ADPKD may be effective in ARPKD as well. Successful therapeutic interventions for childhood PKD will, therefore, be guided by knowledge of these molecular interactions, as well as a number of clinical parameters, such as the stage of the disease and the rate of disease progression.
More Related Videos
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
01:20Acute Kidney Injury V: Interprofessional Care
01:25Chronic Kidney Disease I: Introduction
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:26Kidney Transplant II: Surgical Procedure
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention